adjuvant therapy

• 

Perioperative nivolumab in intermediate/high risk kidney cancer patients

By Sharon Deveson Kell|2024-07-01T08:31:17+00:001 Jul 2024|Drug treatments|

The standard of care for patients with intermediate/high risk kidney [...]

Read More

Comments Off on Perioperative nivolumab in intermediate/high risk kidney cancer patients

• 

Adjuvant pembrolizumab prolongs overall survival for kidney cancer patients

By Sharon Deveson Kell|2024-10-07T09:10:15+00:0022 Apr 2024|Drug treatments|

Surgery (partial or radical nephrectomy) is the standard of care [...]

Read More

Comments Off on Adjuvant pembrolizumab prolongs overall survival for kidney cancer patients

• 

Summary of kidney cancer highlights from ASCO GU 2024

By Sharon Deveson Kell|2024-02-07T08:22:40+00:007 Feb 2024|Drug treatments|

This year’s American Society of Clinical Oncology Genitourinary Cancers (ASCO [...]

Read More

Comments Off on Summary of kidney cancer highlights from ASCO GU 2024

• 

Adjuvant therapy for kidney cancer

By Sharon Deveson Kell|2023-06-23T07:53:54+00:0023 Jun 2023|Drug treatments|

Adjuvant therapy aims to reduce the risk of the cancer [...]

Read More

Comments Off on Adjuvant therapy for kidney cancer

• 

Adjuvant nivolumab plus ipilimumab for localised kidney cancer

By Sharon Deveson Kell|2023-03-20T09:50:05+00:0020 Mar 2023|Drug treatments|

In this randomised phase 3 trial, the effectiveness and safety [...]

Read More

Comments Off on Adjuvant nivolumab plus ipilimumab for localised kidney cancer

• 

Adjuvant nivolumab plus ipilimumab in localised kidney cancer

By Sharon Deveson Kell|2023-02-27T10:20:33+00:0027 Feb 2023|Drug treatments|

A recent phase 3 study called CheckMate 914 has shown [...]

Read More

Comments Off on Adjuvant nivolumab plus ipilimumab in localised kidney cancer

• 

ASCO GU 2023: Adjuvant pembrolizumab for different risks and stages of kidney cancer

By Sharon Deveson Kell|2023-02-22T09:34:55+00:0022 Feb 2023|Drug treatments|

At the American Society of Clinical Oncology Genitourinary Cancers Symposium [...]

Read More

Comments Off on ASCO GU 2023: Adjuvant pembrolizumab for different risks and stages of kidney cancer

• 

ASCO GU 2023: Patient perception of benefits and risks of adjuvant therapy for kidney cancer

By Sharon Deveson Kell|2023-02-22T09:52:33+00:0022 Feb 2023|Drug treatments|

At the American Society of Clinical Oncology Genitourinary Cancers Symposium [...]

Read More

Comments Off on ASCO GU 2023: Patient perception of benefits and risks of adjuvant therapy for kidney cancer

• 

Adjuvant pembrolizumab approved in Scotland

By Sharon Deveson Kell|2022-10-11T09:50:08+00:0011 Oct 2022|Drug treatments|

Yesterday is was announced that the Scottish Medicines Consortium (SMC) [...]

Read More

Comments Off on Adjuvant pembrolizumab approved in Scotland

• 

Adjuvant pembrolizumab approved by NICE

By Sharon Deveson Kell|2022-10-25T08:05:58+00:0026 Sep 2022|Drug treatments|

Late last week we learnt that the National Institute for [...]

Read More

Comments Off on Adjuvant pembrolizumab approved by NICE